Skip to main content

Table 3 Cox regression model analysis for distant recurrence and disease-free survival

From: The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial)

Variable HR (95%CI) p
DR
 Recurrence Score (50 unit) 3.36 (1.88-6.00) < 0.001
 FEC-D 1.15 (0.75-1.75) 0.529
  ≥ 4 positive nodes 2.68 (1.73-4.17) < 0.001
 Tumor size > 20 mm 1.76 (1.12-2.78) 0.015
 SBR grade   0.280
  Grade 2 2.29 (0.81-6.48)  
  Grade 3 2.32 (0.79-6.77)  
 Ki-67 expression 1.19 (0.75-1.88) 0.453
DFS
 Recurrence Score (50 unit) 2.66 (1.62-4.37) < 0.001
 FEC-D 1.10 (0.76-1.59) 0.598
  ≥ 4 positive nodes 2.65 (1.82-3.87) < 0.001
 Tumor size > 20 mm 1.55 (1.06-2.26) 0.024
 Endocrine therapy 0.60 (0.40-0.89) 0.012
 Ki-67 expression 1.17 (0.79-1.74) 0.431
  1. HR hazard ratio, 95CI 95% confidence interval, DR distant recurrence, FEC-D 3 cycles of FEC100 (6 cycles of 5-fluorouracil 500 mg/m2, epirubicin 100 mg/m2, cyclophosphamide 500 mg/m2) followed by 3 cycles of docetaxel 100 mg/m2, SBR Scarff–Bloom Richardson, DFS disease-free survival